BTG has granted the worldwide commercialization and development rights of BGC 945, a novel anticancer compound, to Onyx (ONXX) in exchange for a potential $320M.
BGC 945 is a novel compound that inhibits thymidylate synthase ((TS)), an enzyme involved in cell growth and division. However, unlike traditional TS inhibitors, BGC 945 enters tumour cells via the alpha-folate receptor, which is over-expressed in certain tumour types, including ovarian, lung, endometrial and mesothelioma cells, but has a restricted expression profile in normal tissues.
Milestones: $72M up to approval and $235M for approval and commercial successes in addition to royalties.
BTG has progressed BGC 945 into late-stage preclinical development in collaboration with The Institute of Cancer Research (ICR) where the compound was discovered. BTG will share approximately 10% of the upfront and milestone revenues it receives relating to BGC 945 with ICR plus a pass-through royalty.